ScandiDos AB (SE:SDOS)
:SDOS
Top Page
ScandiDos AB
(SDOS)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr0.90
▼(-22.09% Downside)
Action:ReiteratedDate:03/22/26
The score is held back primarily by weak financial performance (negative profitability and cash burn alongside a TTM revenue decline) and a bearish technical setup (price below all key moving averages with negative MACD). A debt-free balance sheet and improving loss trends provide some support, but valuation remains demanding with a high P/E and no dividend yield.
Positive Factors
Debt-free balance sheet
A near-zero debt load provides durable financial flexibility: it lowers insolvency risk, preserves access to capital, and lets management prioritize R&D, service expansion or targeted investment without immediate debt servicing pressures, supporting stability over the next 2–6 months.
Negative Factors
Recent revenue decline
A declining top line reduces operating leverage and strains the company’s ability to cover fixed costs and fund growth initiatives. Continued revenue contraction would impede margin recovery and make achieving sustainable profitability more difficult over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A near-zero debt load provides durable financial flexibility: it lowers insolvency risk, preserves access to capital, and lets management prioritize R&D, service expansion or targeted investment without immediate debt servicing pressures, supporting stability over the next 2–6 months.
Read all positive factors
ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr56.90M
Dividend YieldN/A
Average Volume (3M)69.69K
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding57,011,086
10 Day Avg. Volume66,689
30 Day Avg. Volume69,692
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.28
Price to Sales (P/S)0.95
P/FCF Ratio-21.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ScandiDos AB Business Overview & Revenue Model
Company Description
ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose...
How the Company Makes Money
ScandiDos makes money primarily by selling radiotherapy QA products and associated software used by hospitals and cancer treatment centers. Key revenue streams include (1) hardware/system sales of measurement and verification equipment used in rad...
ScandiDos AB Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Apr 2024 | Apr 2023 | Apr 2023 | Apr 2021 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 55.48M | 60.43M | 60.43M | 61.55M | 57.68M | 59.99M |
| Gross Profit | 30.55M | 47.55M | 47.55M | 52.95M | 47.92M | 49.73M |
| EBITDA | -1.13M | -5.79M | -13.36M | -8.26M | -7.11M | -1.58M |
| Net Income | -4.18M | -14.65M | -14.65M | -9.12M | -7.34M | -1.40M |
Balance Sheet | ||||||
| Total Assets | 68.09M | 73.38M | 81.47M | 72.42M | 66.19M | 77.16M |
| Cash, Cash Equivalents and Short-Term Investments | 5.85M | 10.06M | 1.53M | 3.55M | 6.24M | 9.00M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00K |
| Total Liabilities | 26.26M | 28.40M | 37.19M | 30.77M | 28.99M | 31.98M |
| Stockholders Equity | 41.83M | 44.98M | 44.29M | 41.65M | 37.20M | 45.18M |
Cash Flow | ||||||
| Free Cash Flow | -2.88M | -2.71M | -1.46M | -16.31M | -2.31M | 4.08M |
| Operating Cash Flow | -1.63M | 230.00K | 1.49M | -11.90M | 2.39M | 8.64M |
| Investing Cash Flow | -2.89M | -2.94M | -2.94M | -4.37M | -4.77M | -4.63M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 12.33M | -83.00K | -1.66M |
ScandiDos AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:SDOS
ScandiDos AB
1.00
-0.43
-30.21%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.38
0.15
67.26%
DE:2OK
SpectraCure AB
0.01
-0.05
-83.33%
DE:24C
C-Rad AB Class B
2.28
-0.31
-11.82%
DE:LUR
Luxbright AB
0.03
-0.04
-58.57%
DE:MN2
Mentice AB
1.24
-0.72
-36.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.